Fig. 1

Dot plot analysis comparing serum TFPI2 levels in control and patients with renal cell carcinoma (RCC) and receiver operating characteristics analysis of TFPI2 between 2 groups (A), Dot plot analysis comparing serum TFPI2 concentrations in control and patients with clear and non-clear RCC and receiver operating characteristics analysis of TFPI2 among 3 groups (B), and Dot plot analysis comparing serum TFPI2 levels in control and patients with localized or metastatic RCC and receiver operating characteristics analysis of TFPI2 among all 3 groups (C).